title: Postconditioning with α7nAChR agonist attenuates systemic inflammatory response to myocardial ischemia--reperfusion injury in rats.
abstract: The inflammatory response plays a major role in ischemia-reperfusion injury (IRI). Considering that cholinergic stimulation can inhibit inflammatory response through the cholinergic anti-inflammatory pathway (CAP) and the α subunit-containing nicotinic acetylcholine receptor(α7nAChR) expressed by immune cells is an important component of CAP, we assessed the effect of postconditioning with α7nAChR agonist on systemic inflammatory response during the myocardial ischemia-reperfusion process in an in vivo rat model. Thirty Sprague Dawley rats were randomly divided into three groups: sham group, control group, and postconditioning with α7nAChR agonist group (PP group). In the groups other than the sham group, the left anterior descending coronary artery was ligated for 30 min followed by a 180-min reperfusion. At the end of the experiment, the serum levels of troponin I, tumor necrosis factor α, interleukin-6, and high-mobility group box 1 were assayed, and the infarct size was assessed. The results showed that postconditioning with α7nAChR agonist significantly attenuated the systemic inflammatory response to myocardial IRI, as evidenced by decreased serum levels of tumor necrosis factor α and high-mobility group box 1. Also, this treatment protected against myocardial IRI, as shown by reduced infarct size and serum troponin I level.
authors.affiliation: Department of Anesthesiology, Tongren Hospital, Capital Medical University, Beijing, 100730, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Xiong
authors.forename: Yu-Jing
authors.initials: YJ
authors.lastname: Yuan
authors.forename: Fu-Shan
authors.initials: FS
authors.lastname: Xue
authors.forename: Qiang
authors.initials: Q
authors.lastname: Wang
authors.forename: Yi
authors.initials: Y
authors.lastname: Cheng
authors.forename: Rui-Ping
authors.initials: RP
authors.lastname: Li
authors.forename: Xu
authors.initials: X
authors.lastname: Liao
authors.forename: Jian-Hua
authors.initials: JH
authors.lastname: Liu
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001549:Benzamides / Q000494:pharmacology; D001643:Bridged Bicyclo Compounds / Q000494:pharmacology; D024243:HMGB1 Protein / Q000097:blood; D007249:Inflammation / Q000188:drug therapy*; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy* / Q000473:pathology; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D011978:Receptors, Nicotinic / Q000378:metabolism*; D019210:Troponin I / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D064569:alpha7 Nicotinic Acetylcholine Receptor
chemical_list: D000893:Anti-Inflammatory Agents; D001549:Benzamides; D001643:Bridged Bicyclo Compounds; C579165:Chrna7 protein, rat; D024243:HMGB1 Protein; D015850:Interleukin-6; C498513:PNU-282987; D011978:Receptors, Nicotinic; D019210:Troponin I; D014409:Tumor Necrosis Factor-alpha; D064569:alpha7 Nicotinic Acetylcholine Receptor